Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase I Trial to Evaluate the Immunomodulatory Effect of RUTI in Individuals With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Treated With Intravesical Bacillus Calmette-Guerin (BCG)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Mar 2023
Price :
$35
*
At a glance
- Drugs Tuberculosis vaccine (Primary) ; Sodium chloride
- Indications Tuberculosis
- Focus Pharmacodynamics
- Acronyms RUTIVAC-1
- Sponsors Archivel Farma
- 20 Mar 2023 Status changed from active, no longer recruiting to completed.
- 27 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 30 Oct 2019 Planned End Date changed from 31 Mar 2024 to 1 Mar 2023.